SLC5A2 and chronic kidney disease: Blood pressure control is known to significantly reduce renal decline and, for a while, the ARBs and the ACEi were the only class of drugs that slowed down renal decline in diabetics with CKD. This study aims to highlight the significant effects of SGLT-2 inhibitors and attempts to understand their mechanism of action.